Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Nevirapine XR 200 mg (4x50mg vs 2x100mg) in Healthy Males
NCT02194218Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2009
- Primary completion
- Nov 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of nevirapine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity and Maximum measured concentration of the analyte in plasma. Started Sep 2009; status: completed.
02
Drugs
nevirapine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02194218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194218.